Plain-English translation of NCT06636656 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative Colitis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called BI 3032950 for people with moderate to severe ulcerative colitis who have not responded well to previous treatments. The study has two parts: first, you'll receive the medication as an infusion through a vein every 4 weeks for 12 weeks; then, if it's working, you'll switch to injecting the medication under your skin every 4 weeks for up to 2 years. The goal is to see if this treatment can reduce the symptoms and inflammation of ulcerative colitis.
Many people with ulcerative colitis don't respond well to current treatments or can't tolerate them. This trial is testing whether this new medication offers a better option for those patients who need more effective relief from their symptoms.
You likely qualify if…
You likely don't qualify if…
You'll start by receiving the medication as an intravenous infusion every 4 weeks for 12 weeks (Part A). At the 12-week mark, your doctor will check whether you're responding to treatment. If you are, you'll move into Part B and begin giving yourself injections under the skin every 4 weeks for up to 2 years. Throughout the study, you'll visit your doctor every 4 weeks for check-ups that include blood and stool samples, and periodic procedures (endoscopies) where a camera is used to look inside your colon. Your doctor will also monitor you for any side effects.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States